#Type2Diabetes #DiabetesCare #GLP1 #Semaglutide #Tirzepatide #SGLT2Inhibitors #Endocrinology #PharmaMarketIntelligence #MarketResearch #DrugDevelopment #Biopharma #CardiometabolicHealth #HealthcareInnovation #PharmaCommercial To view or add a comment, sign in Kailera Therapeutics Therapeutics has reported positive Phase 3 results for oral GLP-1 candidate KAI-7535 in obesity and type 2 diabetes, although high gastrointestinal event rates remain a major commercial and clinical concern.#KaileraTherapeutics #KAI7535 #GLP1 #ObesityTreatment #Type2Diabetes #ClinicalTrials #Biotechnology #WeightLoss #MetabolicDisease #KLRA To view or add a comment, sign in Tsunami of LDL-lowering drugs, yet a high incidence of vascular plaques and heart attacks is still killing people
Research shows that when we consume ultra-processed foods, the hormones that signal to the brain to lower hunger and make us feel full are much lower than when we eat whole foods
Like its injectable counterpart, the oral Wegovy pill uses the same active ingredient - semaglutide - to support weight loss, but it must be taken on an empty stomach at least 30 minutes before food or other medications
While normal, these fluctuations can be frustrating, especially when youre doing everything right, yet the number on the scale remains stagnant